Ongoing trials evaluating tailored adjuvant therapy in patients with HER2+ cancer and residual disease after HER2-directed neoadjuvant therapy include DESTINY-Breast05 (NCT04622319) and COMPASS-RD (NCT04457596). The gene discussed is ERBB2; the disease is cancer.